{
    "2020-01-31": [
        [
            {
                "time": "2020-01-30",
                "original_text": "Edited Transcript of LLY earnings conference call or presentation 30-Jan-20 2:00pm GMT",
                "features": {
                    "keywords": [
                        "LLY",
                        "earnings",
                        "conference",
                        "call",
                        "presentation"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "Eli Lilly prices migraine therapy at $640 for pack of eight pills",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "migraine",
                        "therapy",
                        "pricing"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "Lilly's REYVOWâ„¢ (lasmiditan) C-V, the First and Only Medicine in a New Class of Acute Treatment for Migraine (ditan), Now Available for Prescription",
                "features": {
                    "keywords": [
                        "REYVOW",
                        "lasmiditan",
                        "migraine",
                        "treatment"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative",
                "features": {
                    "keywords": [
                        "LLY",
                        "PFE",
                        "Q4",
                        "results",
                        "JNJ",
                        "vaccine",
                        "coronavirus"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "Bayer Seeks FDA Approval for New Formulation of Nifurtimox",
                "features": {
                    "keywords": [
                        "Bayer",
                        "FDA",
                        "approval",
                        "Nifurtimox"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "The Daily Biotech Pulse: Amgen Hurt By Generic Competition, Nanoviricides Confirms Working On Wuhan Virus, Arcutis IPO",
                "features": {
                    "keywords": [
                        "Amgen",
                        "generic",
                        "competition",
                        "Nanoviricides",
                        "Wuhan",
                        "virus",
                        "Arcutis",
                        "IPO"
                    ],
                    "sentiment_score": 0.4,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2020-01-30",
                "original_text": "CHMP Recommends Approval of Lilly's New Fast-Acting Mealtime Insulin to Improve Glycemic Control in Adults with Diabetes",
                "features": {
                    "keywords": [
                        "CHMP",
                        "Lilly",
                        "insulin",
                        "glycemic",
                        "control",
                        "diabetes"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}